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Abstract
Background: Olfactory dysfunction in MS patients is reported in the literature. MRI of the olfactory bulb (OB) is discussed as
a promising new testing method for measuring olfactory function (OF). Aim of this study was to explore reasons for and
optimize the detection of olfactory dysfunction in MS patients with MRI.
Materials and Methods: OB and olfactory brain volume was assessed within 34 MS patients by manual segmentation.
Olfactory function was tested using the Threshold-Discrimination-Identification-Test (TDI), gustatory function was tested
using Taste Strips (TST).
Results: 41% of the MS patients displayed olfactory dysfunction (8% of the control group), 16% displayed gustatory
dysfunction (5% of the control group). There was a correlation between the OB volume and the number and volume of MS
lesions in the olfactory brain. Olfactory brain volume correlated with the volume of lesions in the olfactory brain and the
EDSS score. The TST score correlated with the number and volume of lesions in the olfactory brain.
Conclusion: The correlation between a higher number and volume of MS lesions with a decreased OB and olfactory brain
volume could help to explain olfactory dysfunction.
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Introduction
MS can be diagnosed using the McDonald criteria [1]. MRI is
the imaging method of choice with inflammatory diseases of the
CNS and the most sensible method in the diagnosis of MS [2].
MRI serves to depict acute as well as chronic MS lesions and their
volume and allows physicians to measure the volume of additional
regions in the brain. Olfactory disorders increasingly occur with
Parkinson and Alzheimer’s disease, but with less frequency with
other neurodegenerative diseases [3,4]. They often occur as early
symptoms of these diseases. There are some scientific studies
already that report olfactory disorders in MS patients at a rate of
15% [5], 22.5% [6] and 38.5% [7].
Our study wants to examine pathological tissue changes and
volume changes of the olfactory brain and of the olfactory bulb
(OB) of MS patients and correlate them with their olfactory and
gustatory function. The aim is to investigate possible causes of the
origin of olfactory disorders in MS patients in greater depth. For
this purpose, volumetric measurements of the OB as well as the
olfactory brain were performed as objective examination method
for the first time. The volumes were determined with manual
segmentation. The exact number, localisation and volume of the
lesions were determined using a standardised MRI protocol
specially developed for our study. Olfactory testing was performed
using the tripartide Threshold-Discrimination-Identification-Test
(TDI).
Materials and Methods
The study was performed in the time from January 2009 until
November 2009. Ethical approval and trial registration was
obtained by the medical ethics comittee of Charite ´, University of
Berlin. Written consent was required to participate in the study. 34
prospective patients (24 women, 10 men, 22–65 years, Ø 41 years,
mean disease duration 6 years) were examined. 25 patients had
relapsing-remitting MS, five patients primary progressive and four
patients secondary progressive MS. The patients were included in
resp. excluded from the study after an ENT and neurological
examination as well as by completing two questionnaires. Patients
with the diagnosis MS (McDonald criteria, revised version 2005)
were included in the study. Exclusion criteria were: pregnancy, age
below 18 or over 65, olfactory disorders with a different genesis
(post-infectious, post-traumatic, sinunasal, infections of the upper
respiratory tract, tumours treated with radiation or chemotherapy,
allergies, patients suffering from depression, Parkinson’s or
Alzheimer’s disease). Patients taking drugs that could cause
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19702olfactory dysfunction as for example methotrexat, amitryptilin,
certain antibiotics and D-Penicillamine were excluded by the
questionnaires. Furthermore patients receiving corticosteroid
treatment up to six weeks before testing were excluded from the
study because corticosteroids can have an effect on the OF [8]. To
exclude dementia, the prospective patients were submitted to the
Mini Mental State Examination (MMSE) [9]. A total score of at
least 24 points was defined as exclusion criterion. Patients with
grave physical disabilities were excluded using the Expanded
Disability Status Scale (EDSS) [10]. A value of below seven was
the threshold value for participation in the study. To exclude
depression, a Becks Depression Inventory test (BDI) was
performed. The BDI is a self-evaluation method for recording
the severity of symptoms of depression [11]. MS patients show a
higher depression level [12]. Disease-related symptoms, e.g.
increased fatigue, lead to false higher scores in the BDI test.
Adapted to the patients in our study, we defined a score of below
15 points as exclusion criterion. Patients with test scores of above
15 were tested once again by a psychologist using the Hamilton
Rating Scale for Depression and the Hamilton Anxiety Rating
Scale in an external assessment.
A complete ENT examination with endoscopy for exact
anatomic evaluation of the nasal passage, the sinuses, damage to
the nasal mucosa as well as the presence of polyps was performed to
exclude olfactory disorders of another origin. Exemption criteria
also applied for the participation in the MRI examination. The
olfactory capacity was evaluated using the tripartide TDI test
recommended bythe ‘‘WorkingGroupOlfactologyand Gustology’’
of the German ENT Society (standardised, reliability r=0.72) [13].
The Threshold test consists of 48 sniffing sticks with a 16-stage
dilution series of n-butanol for determining the olfactory perception
threshold of a patient. The discrimination test consists of 48 sniffing
sticks to test the distinction of smells. Everyday smells have to be
identified with the identification test. A TDI value of less than 16
means anosmia, up to 30 points hyposmia and above 30.5 points
normosmia [14]. Paper taste test strips (TST) by Burghart, Wedel,
Germany, were used to determine the sense of taste [15]. The 16-
part test checks the four tastes sweet, sour, salty and bitter in four
different concentrationseach. Thetest strip is placedinthe centreof
the frontthird of thetop ofthetongue. Priorto eachapplication,the
mouth is rinsed with water. A test value of below 9 indicates a
reduced sense of taste.
The patients were examined on a 1.5 Tesla MRI system
(Symphony Vision, Siemens, Erlangen) using a standardised
protocol to visualise the OB and the olfactory brain. The protocol
contained 3 mm T2 turbo spin echo sequences (TR 3070 msec,
TE 107 msec, Matrix 2566192, FOV 250 mm). 3 mm proton
density sequences (TR 3070 msec, TE 18 msec, Matrix 2566192,
FOV 250 mm) were applied to determine the MS lesion load by
using axial sections. 3 mm T1-weighted sequences (TR 600 msec,
TE 14 msec, Matrix 2566192, FOV 250 mm) were used for
volumetric measurements of the olfactory brain.
Isotropic, 0.5 mm thick, high-resolution, strongly T2-weighed
CISS sequences (constructive interference in steady state, TR
8.56 msec, TE 4.28 msec, Matrix 2566205, FOV 130 mm) were
performed additionally for volumetry of the OB. Gadolinum was
applied as contrast agent to allow a detailed assessment of the MS
lesions.
The olfactory brain was defined as the piriform and entorhinal
cortex, front agranular regions of the insular lobe up to the
anterior comissure, orbitofrontal cortex. White matter in between
these regions was also considered as part of the olfactory brain in
order to take into account the fact that connections could have
been damaged by MS lesions [16].
The volume of the OB (Figure 1) and the olfactory brain was
determined with MRI by circumnavigating the contours in axial
sections with the computer software Amira 3.2.
We determined the number and volume of the lesions in the
olfactory brain as well as in the rest of the brain. The examiners
were blinded to the patient’s olfactory test and EDSS scores. MRI
measurements, olfactory and neurological testing have been
performed on the same day.
Statistical analysis was performed with SPSS (17.0, Chicago,
USA). Correlations were determined with a bivariate regression
analysis. The results of the MRI evaluation were compared with
smell and taste test values using the Pearson and Spearman
correlation. The significance level was defined at #0.05.
The Welch test and the Brown-Forsythe test were used as
statistic test method to check the equality of the mean values of
different test parameters in patients with different types of
progression. The Mann-Whitney U-test for independent samples
was used to compare different control samples.
The patients were recruited continuously from the MS centre,
Charite ´ Campus Mitte. A healthy control group of 30 persons
whose gender, age and smoking habits coincided with that of the
patients were recruited among the patients’ family members as
well as among the hospital staff. All participants of the control
group had to complete the same questionnaires and received an
ENT examination in order to exclude the same causes for
olfactory dysfunction as for the MS patients.
Results
34 MS patients and 30 healthy control persons were examined.
The volume of the OB (Table 1) of the 34 patients correlated with
the number of MS lesions in the olfactory brain (r=20.34,
p,0.05) as well with the volume of the MS lesions in the olfactory
brain (r=20.37, p,0.05).
The volume of the olfactory brain correlated with the volume of
the lesions in the olfactory brain (r=20.33, p=0.05) and the
EDSS value (r=20.37, p,0.05). A significant difference of
p=0.03 was observed between the average volumes of the
patient’s olfactory brain with different types of progression of MS.
The volumes of the patients with primary and secondary
progressive form were lesser than those with relapsing-remitting
progressive form.
Subjective olfactometry using sniffing sticks showed hyposmia in
41% of 34 MS patients (Table 2). In the healthy control group, 8%
of the control persons showed hyposmia. 71% of MS patients with
a decreased OB volume and 83% with a decreased olfactory brain
Figure 1. CISS sequence of OB, axial view.
doi:10.1371/journal.pone.0019702.g001
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strip test. 16% of 25 patients had a gustatory dysfunction. In the
control group, 5% of the patients had a taste disorder.
The TST value correlated with the number of lesions in the
olfactory brain (r=20.49, p,0.05) as well as their volumes
(r=20.52, p,0.05).
The TDI value correlated with the EDSS score (r=20.54,
p,0.01).
Discussion
The olfactory sense is of great importance in everyday life. The
olfactory organ is a control function of the body and warns us
about toxic substances and spoilt food. Some neurological
disorders go hand in hand with olfactory disorders [3,4]. Detecting
olfactory disorders is becoming increasingly important in the
research of neurodegenerative diseases [5].
There is a substantial need for diagnosis and the significance of
imaging the olfactory system is also increasing continuously [17].
Special attention is paid to the OB, which seems to be an image
of the neuronal afference of smelling due to its high plasticity [18].
A significant correlation between the OB volume and the olfactory
ability was determined in several studies [19,20,21].
The olfactory ability is reduced with increasing OB hypoplasia
[19,20,21]. An OB volume of ,100 mm
3 was determined as the
cut-off value for a reduced OB volume [22].
In several studies, reduced OB volumes were determined in
patients with olfactory disorders of a post-infectious, post-
traumatic and sinunasal genesis [23,24,25]. A reduced OB volume
was also observed in patients suffering from Alzheimer’s disease
and schizophrenia [26,27]. The OB volumes were not reduced in
patients suffering from Parkinson’s disease [28].
In our study, we investigated the volume of the OB and the
olfactory brain in MS patients and compared this to the number
and volume of pathological lesions.
The OB volume of the 34 MS patients was diminished with a
mean value of 128 mm
3 compared to the standard values of the
normal population with the same age (134 mm
3) [21]. The
correlation of number and volume of the plaques in the olfactory
brain with the OB volume could explain the variability of the OB
volumes in MS patients. The OB volume decreases with an
increasing number and volume of MS lesions in the olfactory
brain. These results may help to explain the occurrence of
olfactory disorders in MS patients.
The olfactory brain volume correlated with the volume of MS
lesions in the olfactory brain as well as the EDSS score. A reduced
olfactory brain volume was detected in two studies with patients
suffering from Parkinson’s and schizophrenia [29,30]. The larger
the volume of the MS lesions in the olfactory brain, the more
pronounced was the hypoplasia of the olfactory brain. 83% of
patients with an olfactory brain volume of below 30000 mm
3
displayed hyposmia. This correlation may also serve to explain
olfactory disorders in MS patients. The olfactory brain volumes in
MS patients with primary and secondary progression were
significantly smaller than those of MS patients with relapsing-
remitting progression. Demyelination with axon destruction results
with chronic progredient progression, which might explain this
significant difference in volume.
The olfactory brain volume as well as the TDI value correlated
with the EDSS score, which provides information about the degree
of disability oftheMS patient. SeveralMS patients reported about a
subjective improvement resp. deterioration of their olfactory sense
in case of changed physical symptoms, e.g. during an acute episode.
The TDI score seems to uncover changes in the olfactory capacity
in MS patients. The TST values correlated with the number and
volume of the lesions in the olfactory brain. On a cortical level, the
gustatory and olfactory systems intersect, above all in the insular
cortex, the amygdala and the orbitofrontal cortex. On downstream
paths of the OB’s mitral cells from the piriform to the orbitofrontal
cortex, the olfactory stimuli are linked with gustatory information in
the anterior insula (multimodal integration).
In our study, we investigated the volume of the OB and
olfactory brain in MS patients for the first time and compared this
Table 1. Results of the MRI examination.
Mean value Standard deviation
Total volume OB 128.0 mm
3 641.54 mm
3
Volume OB right 62.35 mm
3 621.08 mm
3
Volume OB left 65.65 mm
3 622.89 mm
3
Volume Olfactory Brain 38896.79 mm
3 67731.36 mm
3
Number of lesions in the Olfactory Brain 2.38 63.62
Volume lesions in the Olfactory Brain 90.37 mm
3 6171.42 mm
3
Number of lesions in the Non Olfactory Brain 43.35 625.40
Volume of lesions in the Non Olfactory Brain 11599.0 mm
3 614333.61 mm
3
doi:10.1371/journal.pone.0019702.t001
Table 2. Patient data: Results of olfactometry, gustometry
and neurological examinations.
Mean value Standard deviation
Age (years) 41.4 612.4
Duration of disease (years) 6.1 67.9
TDI 31.5 64.0
T (threshold) 6.3 61.8
D (Discrimination) 12.4 62.5
I (Identification) 12.8 61.7
TST 10.8 62.8
EDSS 3.3 62.1
BDI 7.3 66.4
MMSE 28.9 61.1
doi:10.1371/journal.pone.0019702.t002
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higher number and volume of MS lesions in the olfactory brain
with a decreased OB and olfactory brain volume might explain the
occurrence of olfactory dysfunction in MS patients. The results
should be verified in a longitudinal study with a higher number of
patients.
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